Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for reversal of rocuronium-induced neuromuscular blockade in Chinese and European surgical patients
2007-006304-37Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Mar 2008
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in neuromuscular block (NMB) comparing Sugammadex arm with Neostigmine plus atropine arm (2 arms). Primary endpoint: Time to recovery of T4/T1 ratio to 0.9. Started Mar 2008; status: completed.
02
Drugs
Sugammadexneostigmine
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2007-006304-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006304-37.